#ES­MO20: As­traZeneca aims to spur PRO­found shift in prostate can­cer treat­ment with Lyn­parza OS da­ta

As­traZeneca has un­veiled the fi­nal, ma­ture over­all sur­vival da­ta that ce­ment­ed Lyn­parza’s first ap­proval in prostate can­cer ap­proval — tout­ing its lead against ri­vals with the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER